Apart from TNF-α, increased TGF-β levels in circulation of breast cancer patients [160] can activate TAK1 [161,162], which phosphorylates IKK2 as well as NIK [163,164] and inhibits myogenesis by repressing the expression of MyoD [75,165]. Here, TGFB1 is linked to breast carcinoma.